Ítem
Acceso Abierto
Antimicrobial Activity of the Peptide C14R Against Ab Initio Growing and Preformed Biofilms of Candida albicans, Candida parapsilosis and Candidozyma auris
Título de la revista
Autores
Rosenau, Frank
Firacative Ropero, Sandra Carolina
Stenger, Steffen
Wolfgang Knoll
Kleber, Christoph
Ständker, Ludger
Rodriguez-Alfonso, Armando
Preising, Nico
Martell-Huguet, Ernesto M.
Alpízar-Pedraza, Daniel
Fecha
2025-03-01
Directores
ISSN de la revista
Título del volumen
Editor
MDPI
Buscar en:
Métricas alternativas
Resumen
Abstract
Biofilms are the predominant lifeforms of microorganisms, contributing to over 80% of infections, including those caused by Candida species like C. albicans, C. parapsilosis and Candidozyma auris. These species form biofilms on medical devices, making infections challenging to treat, especially with the rise in drug-resistant strains. Candida infections, particularly hospital-acquired ones, are a significant health threat due to their resistance to antifungals and the risk of developing systemic infections (i.e., sepsis). We have previously shown that C14R reduces the viability of C. albicans and C. auris, but not of C. parapsilosis. Here, we show that C14R not only inhibits viability by pore formation, shown in a resazurin reduction assay, and in a C. parapsilosis and fluorescence-based permeabilization assay, but it also halts biofilm maturation and significantly reduces the biomass of preformed biofilms by over 70%. These findings suggest C14R could be an effective option for treating severe fungal infections, offering a potential new treatment approach for biofilm-related diseases. Further research is needed to fully understand its biofilm dispersal potential and to optimize its use for future applications as an antifungal in clinical settings.
Palabras clave
Keywords
Bioquímica , Novel antifungals , Infectious disease , Next-generation antimycotic
